Compounds > 15-hydroxy-5-8-11-13-eicosatetraenoic-acid

15-hydroxy-5-8-11-13-eicosatetraenoic-acid and nafazatrom

15-hydroxy-5-8-11-13-eicosatetraenoic-acid has been researched along with nafazatrom* in 1 studies

Other Studies

1 other study(ies) available for 15-hydroxy-5-8-11-13-eicosatetraenoic-acid and nafazatrom

Article	Year
Inhibition of leukotriene B4 formation in human neutrophils after oral nafazatrom (Bay g 6575). Biochemical pharmacology, 1985, Jun-01, Volume: 34, Issue:11 Three grams of nafazatrom (Bay g 6575), given orally to healthy male volunteers in a single dose, significantly reduce the formation of leukotriene B4 in polymorphonuclear leukocytes. LTB4 synthesis fell from 57.1 +/- 17.0 ng/10(7) PMNL, mean +/- S.D., in control to 34.3 +/- 14.4 ng/10(7) PMNL 3 hr after nafazatrom (2 P less than 0.001). In vitro, nafazatrom inhibited LTB4 formation in human PMNL in a dose dependent manner. At 1 microM nafazatrom LTB4 formation was reduced to 65% of the control value. Nafazatrom had no effect on the excretion of 2,3-dinor-6-keto-PGF1 alpha and 2,3-dinor-TXB2, the major urinary metabolites of endogenously synthesized PGI2 and TXA2, respectively. Serum levels of TXB2 in clotted whole blood also remained unchanged. The inhibitory effect of nafazatrom on leukotriene biosynthesis in human PMNL suggests a therapeutic potential of this drug in processes like allergy and chronic inflammation, where leukotrienes play a pathogenetic role. Topics: Administration, Oral; Adult; Epoprostenol; Fibrinolytic Agents; Humans; Hydroxyeicosatetraenoic Acids; In Vitro Techniques; Leukotriene B4; Male; Neutrophils; Pyrazoles; Pyrazolones	1985

Article

Year

Inhibition of leukotriene B4 formation in human neutrophils after oral nafazatrom (Bay g 6575).

Biochemical pharmacology, 1985, Jun-01, Volume: 34, Issue:11

Three grams of nafazatrom (Bay g 6575), given orally to healthy male volunteers in a single dose, significantly reduce the formation of leukotriene B4 in polymorphonuclear leukocytes. LTB4 synthesis fell from 57.1 +/- 17.0 ng/10(7) PMNL, mean +/- S.D., in control to 34.3 +/- 14.4 ng/10(7) PMNL 3 hr after nafazatrom (2 P less than 0.001). In vitro, nafazatrom inhibited LTB4 formation in human PMNL in a dose dependent manner. At 1 microM nafazatrom LTB4 formation was reduced to 65% of the control value. Nafazatrom had no effect on the excretion of 2,3-dinor-6-keto-PGF1 alpha and 2,3-dinor-TXB2, the major urinary metabolites of endogenously synthesized PGI2 and TXA2, respectively. Serum levels of TXB2 in clotted whole blood also remained unchanged. The inhibitory effect of nafazatrom on leukotriene biosynthesis in human PMNL suggests a therapeutic potential of this drug in processes like allergy and chronic inflammation, where leukotrienes play a pathogenetic role.

Topics: Administration, Oral; Adult; Epoprostenol; Fibrinolytic Agents; Humans; Hydroxyeicosatetraenoic Acids; In Vitro Techniques; Leukotriene B4; Male; Neutrophils; Pyrazoles; Pyrazolones

1985